Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC and Pembrolizumab in Advanced Sarcoma
NCT03069378Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Jul 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of talimogene laherparepvec, pembrolizumab in sarcoma, epithelioid sarcoma (ES), cutaneous angiosarcoma (cAS), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2017; status: active, not recruiting.
02
Drugs
talimogene laherparepvecpembrolizumab
03
Conditions
sarcomaepithelioid sarcoma (ES)cutaneous angiosarcoma (cAS)
Beyond the preview
Go deeper on NCT03069378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069378.